Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPREPP-SA: Pharmacy-Initiated PrEP in South Africa
NCT07006246Phase 4Active, not recruiting
- Start
- May 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of emtricitabine + tenofovir disoproxil, lamivudine + tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV). Started May 2023; status: active, not recruiting.
02
Drugs
emtricitabine + tenofovir disoproxillamivudine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07006246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006246.